Molecular Weight ：151.16
CAS NO.：56-91-7
Chemical Properties & Use
Chemical Properties: white flaky texture or crystalline powder; the hydrate dissolves in boiling water, slightly soluble in water, almost insoluble in ethanol, benzene, chloroform. Odorless, taste bitter.
Use：Asymmetric synthetic intermediates. hemostatics, fibrinolytic inhibitors, are suitable for various diseases caused by excessive hyperactivity of fibrinolytic enzymes.
Approval Number/ Imported Drug License: 56-91-7
Indication:
1.It is applied to bleedings including those caused by hyperfunction in fibrinolysis process such as lung, liver, pancreas, prostate, thyroid, adrenal glands bleedings and other abnormal bleedings during surgery, postpartum hemorrhage in the obstetrics and gynecology department, pulmonary tuberculosis hemoptysis or blood-stained sputum, hematuria, and prostatic hyperplasia and bleeding, as well as upper gastrointestinal haemorrhage, etc.
2.The efficacy of chronic exudation is obvious, but there is no hemostatic effect on cancer hemorrhage and traumatic hemorrhage.
3.In addition, it can be applied to bleeding caused by streptokinase or urokinase overdose.
Dosage and Administration:
1.Oral: Each time 0.25 ~ 0.5g, 3 times a day, the maximum daily dose is 2g. Children> 5 years old: 0.1g to 0.125g each time, 2~3 times a day.
2.Intravenous injection: Injected slowly by the intravenous route with each single dose of 0.1g~0.3g after it is diluted by 10ml~20ml 5% glucose injection or 0.9% sodium chloride injection. Maximum daily dose is 0.6g. Newborns: each dose 0.02g~0.03g; children > 5 years old: each dose 0.05g~0.1g.
Precautions:
1.Overdose can promote thrombosis. It is forbidden or used with caution for patients with a history of thrombophilia or that of thromboembolism.
2.Should be used with caution by patients with severe renal dysfunction.
Specification:
Injection: each 0.05g (5ml) and 0.1g (10ml).
Tablet: per slice 0.25g
